Eli Lilly Rises Over 2.7% on Launch of 10mg Vial Format of Zepbound

Gelonghui February 25 | Eli Lilly (LLY.US) rose over 2.7%, reaching $905.4. On the news front, Eli Lilly announced that the monthly prices for the 2.5 mg and 5 mg vial versions of its popular weight-loss drug Zepbound will be reduced to $349 and $499 respectively, marking a decrease of approximately $50 from previous levels. Additionally, Eli Lilly has introduced a 10 mg dose vial of Zepbound, priced at $499 per month. Company executives stated that since the launch of Zepbound, more than 10% of patients have started taking the lower-dose version of Zepbound. (Gelonghui)